NCT00530075View on ClinicalTrials.gov

Phase II Study on Gusperimus in Patients With Refractory Wegener's Granulomatosis

PHASE2CompletedINTERVENTIONAL
Enrollment

45

Participants

Timeline

Start Date

December 31, 2003

Primary Completion Date

February 28, 2006

Study Completion Date

February 28, 2006

Conditions
Wegener's Granulomatosis
Interventions
DRUG

Gusperimus

SC, 0.5mg/kg/day, consecutive 21 days administration, 1 to 2 weeks rest, 6 cycles

Trial Locations (7)

2100

Reumatologisk Klinik, Copenhagen

6202

University Hospital Maastricht, Maastricht

12808

General Faculty Hospital, Prague

14186

Karolinska University Hospital, Stockholm

23538

Universitatsklinikum Schleswig-Holstein, Lübeck

EH4 2XU

Western General Hospital, Edinburgh

CB2 2QQ

Addenbrookes Hospital, Cambridge

Sponsors
All Listed Sponsors
lead

Nippon Kayaku Co., Ltd.

INDUSTRY

NCT00530075 - Phase II Study on Gusperimus in Patients With Refractory Wegener's Granulomatosis | Biotech Hunter | Biotech Hunter